| Jennifer Liedel, MD | |
|
180 Harvester Dr Ste 110, Burr Ridge, IL 60527-6686 | |
| (773) 834-4064 | |
| Not Available |
| Full Name | Jennifer Liedel |
|---|---|
| Gender | Female |
| Speciality | Pediatrics - Pediatric Critical Care Medicine |
| Location | 180 Harvester Dr Ste 110, Burr Ridge, Illinois |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336299379 | NPI | - | NPPES |
| 036102039 | Medicaid | IL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080P0203X | Pediatrics - Pediatric Critical Care Medicine | 036102039 (Illinois) | Primary |
| Entity Name | The Nemours Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386658615 PECOS PAC ID: 9537072483 Enrollment ID: O20040109000252 |
News Archive
Even before the 2010 U.S. Census confirms it, one Los Angeles company's consistent growth throughout the recession reveals an increasing need for language services, especially for companies in the healthcare and financial services sectors.
Fisher Wallace Laboratories today announced the results of a brain stimulation study involving the Fisher Wallace Cranial Stimulator, a portable medical device that treats depression, anxiety and insomnia. The study, published in The Neuroscientist and authored by Dr. Felipe Fregni, assistant professor in neurology at Harvard Medical School, analyzes a decade's worth of research on the brain stimulation technology used by the Fisher Wallace Cranial Stimulator.
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
One of the defining characteristics of solid tumors is the development of a network of new blood vessels to nourish the rapidly reproducing malignant cells. Now, using a nanoparticle targeted to those new blood vessels, a joint academic-industrial research team, led by investigators from the Siteman Center of Cancer Nanotechnology Excellence, has developed a way to construct a three-dimensional (3-D) map of tumor-induced angiogenesis and monitor the effects of drug therapies on those new blood vessels.
The Organic Trade Association today called on the U.S. Departments of Agriculture and Health & Human Services to encourage those seeking to minimize their exposure to toxic chemicals to look for the USDA Organic label wherever they shop by revising the draft Dietary Guidelines for Americans 2010.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Liedel, MD 10140 Centurion Pkwy N, Jacksonville, FL 32256-0532 Ph: (904) 697-4127 | Jennifer Liedel, MD 180 Harvester Dr Ste 110, Burr Ridge, IL 60527-6686 Ph: (773) 834-4064 |
News Archive
Even before the 2010 U.S. Census confirms it, one Los Angeles company's consistent growth throughout the recession reveals an increasing need for language services, especially for companies in the healthcare and financial services sectors.
Fisher Wallace Laboratories today announced the results of a brain stimulation study involving the Fisher Wallace Cranial Stimulator, a portable medical device that treats depression, anxiety and insomnia. The study, published in The Neuroscientist and authored by Dr. Felipe Fregni, assistant professor in neurology at Harvard Medical School, analyzes a decade's worth of research on the brain stimulation technology used by the Fisher Wallace Cranial Stimulator.
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
One of the defining characteristics of solid tumors is the development of a network of new blood vessels to nourish the rapidly reproducing malignant cells. Now, using a nanoparticle targeted to those new blood vessels, a joint academic-industrial research team, led by investigators from the Siteman Center of Cancer Nanotechnology Excellence, has developed a way to construct a three-dimensional (3-D) map of tumor-induced angiogenesis and monitor the effects of drug therapies on those new blood vessels.
The Organic Trade Association today called on the U.S. Departments of Agriculture and Health & Human Services to encourage those seeking to minimize their exposure to toxic chemicals to look for the USDA Organic label wherever they shop by revising the draft Dietary Guidelines for Americans 2010.
› Verified 1 days ago
Ruth R Rudinsky, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 180 Harvester Dr Ste 110, Burr Ridge, IL 60527 Phone: 773-834-4064 | |
John F Marcinak, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 180 Harvester Dr Ste 110, Burr Ridge, IL 60527 Phone: 773-834-4064 | |
Eric C Beyer, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 180 Harvester Dr Ste 110, Burr Ridge, IL 60527 Phone: 773-834-4064 | |
Jean Marie Schied, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 180 Harvester Dr Ste 110, Burr Ridge, IL 60527 Phone: 773-834-4064 | |
Elizabeth E Littlejohn, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 180 Harvester Dr Ste 110, Burr Ridge, IL 60527 Phone: 773-834-4064 | |
Erika Claud, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 180 Harvester Dr Ste 110, Burr Ridge, IL 60527 Phone: 773-834-4064 | |
Martin A Bazi, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 180 Harvester Dr Ste 110, Burr Ridge, IL 60527 Phone: 773-834-4064 |